EWTX - Company ID 0001710072
The table below shows Edgewise Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $31.57M | $47.55M | $42.65M | $37.48M | $33.56M | $36.76M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $14.57M |
| $14.39M |
| $11.46M |
| $9.38M |
| $9.05M |
| $9.20M |
| Operating income | -$46.14M | -$61.94M | -$54.12M | -$46.86M | -$42.61M | -$45.96M |
| Income tax | $155.33M | - | - | - | - | - |
| Net income | $1.17B | -$57.33M | -$49.01M | -$40.67M | -$36.12M | -$40.80M |
| EPS (diluted) | $9.65 | -$0.53 | -$0.46 | -$0.39 | -$0.34 | -$0.43 |